A. Menarini Asia-Pacific Holdings Pte. Ltd, a subsidiary of the Italy-based Menarini Group, has entered into a long-term exclusive licensing agreement with Japan-headquartered Astellas Pharma Inc (TYO: 4503). The partnership grants Menarini the rights to develop, manufacture, and commercialize the orally administered Janus kinase (JAK) inhibitor Smyraf (peficitinib hydrobromide) in Taiwan. The agreement includes the 50mg and 100mg dosage tablets of the drug, which is indicated for the treatment of rheumatoid arthritis (RA).
Financial Terms and Royalty Agreement
According to the terms of the deal, Astellas will receive total payments of up to EUR 5.5 million (USD 5.9 million), comprising upfront and milestone payments. Additionally, Menarini has committed to paying Astellas a high-single digit percentage royalty on net sales of Smyraf. The agreement also provides Menarini with the option to extend the licensing rights to select South-East Asian markets, broadening the potential reach of the drug in the region.
Smyraf’s Market Position and Patent Protection
Smyraf is already marketed in Japan for the treatment of RA in patients who have not responded well to conventional therapies. In Taiwan, the drug has received approval and is under patent protection until 2032, providing a strong foundation for its commercialization and growth in the territory.-Fineline Info & Tech
